Apotek Produktion & Laboratorier AB (APL) is a prominent Swedish pharmaceutical company and one of Europe's leading contract development and manufacturing organizations (CDMOs) for extemporaneous medicinal products and stock preparations. Wholly owned by the Swedish state, APL plays a vital role in the Swedish healthcare system by ensuring the availability of niche and essential medicines. They offer a wide range of services, from pharmaceutical development to full-scale commercial manufacturing, catering to both national healthcare needs and the broader pharmaceutical industry.
The headquarters houses central administration, strategic management, research and development (R&D) laboratories, and some specialized pharmaceutical production units.
Modern pharmaceutical production facilities adhering to Good Manufacturing Practice (GMP) standards, advanced research laboratories, and office spaces designed for collaboration.
APL fosters a work culture centered on quality, scientific innovation, patient safety, and collaboration. As a key player in public health, there's a strong sense of purpose among employees, with an emphasis on continuous learning and development in a highly regulated environment.
The headquarters is significant as it orchestrates APL's mission to supply essential medicines, develop new pharmaceutical solutions, and contribute to Sweden's national pharmaceutical preparedness. It's the core of their strategic and operational decision-making.
While Apotek Produktion & Laboratorier AB's primary focus is on serving the Swedish healthcare system and the Nordic market, it also functions as a Contract Development and Manufacturing Organization (CDMO) for a broader range of clients. APL provides services such as pharmaceutical development, manufacturing of clinical trial materials, and commercial production for pharmaceutical companies in Europe and potentially other international markets. Their expertise in extemporaneous drugs, orphan drugs, and specialized formulations gives them a niche role in the global pharmaceutical landscape.
Prismavägen 2
Kungens Kurva
Stockholms län
Sweden
Address: Aminogatan 25-27, 431 53 Mölndal
Serves as a key manufacturing site for Western Sweden and contributes significantly to APL's overall production capacity and research capabilities.
Address: Agneslundsvägen 10 C, 202 11 Malmö
Key site for Southern Sweden, enhancing APL's ability to meet diverse pharmaceutical needs and support regional healthcare demands.
Address: Formvägen 5B, 906 21 Umeå
Important for pharmaceutical supply and development in Northern Sweden, ensuring broader geographical coverage for APL's services.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, APL (Apotek Produktion & Laboratorier AB)' leadership includes:
APL (Apotek Produktion & Laboratorier AB) has been backed by several prominent investors over the years, including:
The primary executive change at Apotek Produktion & Laboratorier AB in the last 12 months involved the Chief Executive Officer role. Erik Haeffler stepped down, and Helena Norman was appointed as acting CEO.
Discover the tools APL (Apotek Produktion & Laboratorier AB) uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Apotek Produktion & Laboratorier AB typically uses a standard email format common in Swedish organizations, which is firstname.lastname@apl.se. This format is widely adopted for professional communication.
förnamn.efternamn@apl.se (firstname.lastname@apl.se)
Format
helena.norman@apl.se
Example
90%
Success rate
apl.se • 2023-12-20
The Swedish government has assigned Apotek Produktion & Laboratorier AB an expanded role in national pharmaceutical preparedness. This includes developing capabilities for large-scale vaccine filling and ensuring the availability of critical medicines during crises....more
apl.se • 2023-10-02
Helena Norman has been appointed as the acting CEO of Apotek Produktion & Laboratorier AB, effective October 2, 2023. She succeeds Erik Haeffler. Helena has been with APL since 2018, most recently as Head of R&D....more
apl.se • 2023-05-04
Apotek Produktion & Laboratorier AB and Lipum AB have entered into a collaboration for the pharmaceutical development and future manufacturing of Lipum's biological drug candidate SOL-116 in an eye drop formulation for patients with chronic eye inflammation....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including APL (Apotek Produktion & Laboratorier AB), are just a search away.